Peter Greenleaf

Peter Greenleaf

Chief Executive Officer bei AURINIA PHARMACEUTICALS INC.

Vermögen: 8 Mio $ am 31.03.2024

54 Jahre
Health Technology
Commercial Services
Finance

Profil

Peter S.
Greenleaf
currently works at Aurinia Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2019, Maryland Venture Fund, as Chairman, Revolo Biotherapeutics Ltd., as Chairman from 2020, Pharmaceutical Research & Manufacturers of America, as Director, ValenzaBio, Inc., as Director, and Petrichor Healthcare Capital Management LP, as Advisory.
Mr. Greenleaf also formerly worked at Histogenics Corp., as President, Chief Executive Officer & Director from 2013 to 2014, Sucampo Pharmaceuticals LLC, as Chairman & Chief Executive Officer from 2016 to 2018, BioDelivery Sciences International, Inc., as Chairman from 2018 to 2022, Antares Pharma, Inc., as Independent Director from 2018 to 2022, Mast Therapeutics, Inc., as Independent Director, Oldtech, Inc., as Director, Kiora Pharmaceuticals, Inc., as Director from 2018 to 2020, Biotechnology Innovation Organization, as Director, Melinta Subsidiary Corp., as Director, Tech Council of Maryland, Inc., as Director, LigoCyte Pharmaceuticals, Inc., as Director, Mirna Therapeutics, Inc., as Independent Director, Corridor Pharmaceuticals, Inc., as Director, Avalo Therapeutics, Inc., as Director from 2019 to 2020, Savara, Inc., as Director, OS Therapies, Inc., as Director, Centocor, Inc., as VP-US Gastroenterology Commercial Group, MedImmune LLC, as President from 2006 to 2013, US Healthcare, Inc., as Principal, Hallmark Cards, Inc., as Principal, MedImmune Ventures, Inc., as President from 2010 to 2013, Roche Diagnostics Corp., as Principal from 1996 to 1998, and The University of Maryland Baltimore Foundation, Inc., as Trustee.
Mr. Greenleaf received his Masters Business Admin degree from St. Joseph's University and undergraduate degree from Western Connecticut State University.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
06.03.2024 1 522 114 ( 1,05% ) 8 Mio $ 31.03.2024

Aktive Positionen von Peter Greenleaf

UnternehmenPositionBeginn
AURINIA PHARMACEUTICALS INC. Chief Executive Officer 29.04.2019
Consultant / Advisor -
Chairman 17.12.2020
Director/Board Member -
Chairman -
Director/Board Member -
Alle aktiven Positionen von Peter Greenleaf

Ehemalige bekannte Positionen von Peter Greenleaf

UnternehmenPositionEnde
ANTARES PHARMA, INC. Director/Board Member 24.05.2022
BIODELIVERY SCIENCES INTERNATIONAL, INC. Chairman 22.03.2022
AVALO THERAPEUTICS, INC. Chief Executive Officer 15.04.2019
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
Sehen Sie sich die Erfahrung von Peter Greenleaf im Detail an

Ausbildung von Peter Greenleaf

St. Joseph's University Masters Business Admin
Western Connecticut State University Undergraduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Peter Greenleaf im Detail an

Beziehungen

99

Beziehungen ersten Grades

31

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen4
KIORA PHARMACEUTICALS, INC.

Health Technology

AVALO THERAPEUTICS, INC.

Health Technology

AURINIA PHARMACEUTICALS INC.

Health Technology

SAVARA INC.

Health Technology

Private Unternehmen25

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

LigoCyte Pharmaceuticals, Inc.

Health Technology

The University of Maryland Baltimore Foundation, Inc.

Miscellaneous

Finance

Health Technology

Health Technology

Finance

Commercial Services

Health Technology

Commercial Services

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Peter Greenleaf